Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform

Arvinas (NASDAQ:ARVN - Get Free Report) was downgraded by stock analysts at Oppenheimer from an "outperform" rating to a "market perform" rating in a research report issued on Tuesday,Briefing.com Automated Import reports.

ARVN has been the topic of a number of other research reports. Wedbush reissued an "outperform" rating and issued a $57.00 price objective on shares of Arvinas in a research note on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. BTIG Research initiated coverage on shares of Arvinas in a report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price target for the company. Barclays lowered their price objective on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.58.

Arvinas Trading Down 52.4 %

ARVN traded down $9.20 on Tuesday, reaching $8.36. The company had a trading volume of 7,894,065 shares, compared to its average volume of 1,189,344. The company has a market capitalization of $574.73 million, a P/E ratio of -2.98 and a beta of 1.95. The company has a fifty day moving average of $18.22 and a 200-day moving average of $22.38. Arvinas has a one year low of $7.91 and a one year high of $46.62.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the firm earned ($2.53) earnings per share. Research analysts predict that Arvinas will post -3.81 EPS for the current year.

Insider Activity

In other news, insider Ian Taylor sold 9,020 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares of the company's stock, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,572 shares of company stock worth $695,030 over the last 90 days. 5.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas in the fourth quarter worth approximately $28,000. KBC Group NV increased its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after buying an additional 1,255 shares during the period. Quantbot Technologies LP lifted its position in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Arvinas in the 4th quarter worth approximately $171,000. Finally, Tema Etfs LLC acquired a new stake in shares of Arvinas during the 4th quarter valued at $227,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.